



Fruiting date palm (*Phoenix dactylifera*, Khalas variety). The draft genome of date palm assembled by Malek and colleagues has important implications for cultivation and improvement of the crop (p 521).
Credit: Mohammed Sulaiman Khalfan Al-Rawahi.

nature biotechnology

EDITORIAL

- 463 The sequence is dead: long live the genome

NEWS

- 465 First cystic fibrosis drug advances towards approval
467 Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis
468 Stem cell funding resumes
469 Debate re-ignites on contribution of public research to drug development
470 Supreme setback for pharma
470 Blue skies ready for investors
471 Chinese vaccine developers gain WHO imprimatur
472 GM bananas
473 Spat over IMI funding and intellectual property
473 Monsanto dips into algae
473 Bayer's GM rice defeat
474 **NEWS FEATURE:** Raising hairs

BIOENTREPRENEUR

BUILDING A BUSINESS

- 477 What mergers can do for you
Anu Acharya

OPINION AND COMMENT

CORRESPONDENCE

- 480 Intranasal delivery to the brain
480 Quantitative analysis demonstrates most transcription factors require only simple models of specificity
483 Jury remains out on simple models of transcription factor specificity
484 US attitudes toward human embryonic stem cell research
488 Recurrent copy number variations in human induced pluripotent stem cells




New hope for cystic fibrosis treatments, p 465



nature publishing group


Nature Biotechnology (ISSN 1087-0156) is published monthly by Nature Publishing Group, a trading name of Nature America Inc., located at 75 Varick Street, Fl 9, New York, NY 10013-1917. Periodicals postage paid at New York, NY and additional mailing post offices. **Editorial Office:** 75 Varick Street, Fl 9, New York, NY 10013-1917. Tel: (212) 726-9335, Fax: (212) 696-9753. **Annual subscription rates:** USA/Canada: US\$250 (personal), US\$4,048 (institution), US\$4,658 (corporate institution). Canada add 5% GST #104911595RT001; Euro-zone: €202 (personal), €3,214 (institution), €4,011 (corporate institution); Rest of world (excluding China, Japan, Korea): €130 (personal), €2,077 (institution), €2,588 (corporate institution); Japan: Contact NPG Nature Asia-Pacific, Chiyoda Building, 2-37 Ichijiyamachi, Shinjuku-ku, Tokyo 162-0843. Tel: 81 (0)3 3267 8751, Fax: 81 (0)3 3267 8746. **POSTMASTER:** Send address changes to Nature Biotechnology, Subscriptions Department, 75 Varick Street, 9th Floor, New York, NY 10013-1917. **Authorization to photocopy** material for internal or personal use, or internal or personal use of specific clients, is granted by Nature Publishing Group to libraries and others registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided the relevant copyright fee is paid direct to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. Identification code for Nature Biotechnology: 1087-0156/04. **Back issues:** US\$45, Canada add 7% for GST. CPC PUB AGREEMENT #40032744. Printed by Publishers Press, Inc., Lebanon Junction, KY, USA. Copyright © 2011 Nature America, Inc. All rights reserved. Printed in USA.



Adding dosage suppression to the interactome, p 505



Discordant calling of copy number variation, p 512



Generating astrocytes *in vitro*, p528

PATENTS

- 493 **Is silence still golden? Mapping the RNAi patent landscape**
Per Lundin
- 498 **Recent patent applications related to zinc fingers**

NEWS AND VIEWS

- 499 **MicroRNAs and reprogramming**
Hao-Ming Chang & Richard I Gregory
- 500 **Human peptidome display**
William H Robinson & Lawrence Steinman **i** see also p 535
- 502 **Molecular evolution picks up the PACE**
Adam J Meyer & Andrew D Ellington
- 504 **RESEARCH HIGHLIGHTS**

COMPUTATIONAL BIOLOGY

ANALYSIS

- 505 **Dosage suppression genetic interaction networks enhance functional wiring diagrams of the cell**
Leslie Magtanong, Cheuk Hei Ho, Sarah L Barker, Wei Jiao, Anastasia Baryshnikova, Sondra Bahr, Andrew M Smith, Lawrence E Heisler, John S Choy, Elena Kuzmin, Kerry Andrusiak, Anna Kobylanski, Zhijian Li, Michael Costanzo, Munira A Basrai, Guri Giaever, Corey Nislow, Brenda Andrews & Charles Boone


RESEARCH

ANALYSIS

- 512 **Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants**
Dalila Pinto, Katayoon Darvishi, Xinghua Shi, Diana Rajan, Diane Rigler, Tom Fitzgerald, Anath C Lionel, Bhooma Thiruvahindrapuram, Jeffrey R MacDonald, Ryan Mills, Aparna Prasad, Kristin Noonan, Susan Gribble, Elena Prigmore, Patricia K Donahoe, Richard S Smith, Ji Hyeon Park, Matthew E Hurles, Nigel P Carter, Charles Lee, Stephen W Scherer & Lars Feuk

ARTICLES

- 521 ***De novo* genome sequencing and comparative genomics of date palm (*Phoenix dactylifera*)**
Eman K Al-Dous, Binu George, Maryam E Al-Mahmoud, Moneera Y Al-Jaber, Hao Wang, Yasmeen M Salameh, Eman K Al-Azwani, Srinivasa Chaluvadi, Ana C Pontaroli, Jeremy DeBarry, Vincent Arondel, John Ohlrogge, Imad J Saie, Khaled M Suliman-Elmeer, Jeffrey L Bennetzen, Robert R Kruegger & Joel A Malek
- 528 **Specification of transplantable astroglial subtypes from human pluripotent stem cells**
Robert Krencik, Jason P Weick, Yan Liu, Zhi-Jian Zhang & Su-Chun Zhang
- 535 **Autoantigen discovery with a synthetic human peptidome**
H Benjamin Larman, Zhenming Zhao, Uri Laserson, Mamie Z Li, Alberto Ciccia, M Angelica Martinez Gakidis, George M Church, Santosh Kesari, Emily M LeProust, Nicole L Solimini & Stephen J Elledge **i** see also p 500



Streamlined knockout screens in haploid cells, p 542

LETTERS

542 Global gene disruption in human cells to assign genes to phenotypes by deep sequencing

Jan E Carette, Carla P Guimaraes, Irene Wuethrich, Vincent A Blomen, Malini Varadarajan, Chong Sun, George Bell, Bingbing Yuan, Markus K Muellner, Sebastian M Nijman, Hidde L Ploegh & Thijn R Brummelkamp

CAREERS AND RECRUITMENT

547 Assessing the impact of China's Thousand Talents Program on life sciences innovation

Erik Lundh

550 PEOPLE

ADVERTISEMENTS

Special Report: BioPharma Dealmakers— *Partnering Strategies in rare diseases and Dealmaking trends in oncology*

In two separate features, freelance writers Nuala Moran and Suzanne Elvidge explore how rare diseases have become an attractive deal-making realm for companies large and small, and how the cancer market is proving a persistently dynamic environment for partnering despite the world's financial slowdown. The report was produced with commercial support from the promoting organizations within the section.

